Heidelberg Pharma AG

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in oncology, developing innovative antibody-drug conjugates (ADCs) for targeted cancer therapies. Its primary focus is on creating novel drugs that combine the specificity of antibodies with potent toxins to deliver cytotoxic payloads directly to cancer cells, addressing both hematologic and solid tumors. The company pioneered the use of Amanitin, a toxin derived from the green death cap mushroom, in its proprietary ATAC technology, which targets RNA Polymerase II to overcome therapy resistance and eliminate dormant tumor cells. Notable candidates include HDP-101, a BCMA-ATAC in clinical development for multiple myeloma, and HDP-201, an exatecan-based ADC utilizing a topoisomerase I inhibitor. Headquartered in Ladenburg, Germany, with around 105-122 employees, Heidelberg Pharma AG maintains a robust pipeline across preclinical to Phase III stages and offers contract research services. Founded in 1997, it plays a key role in advancing precision oncology through its ADC toolbox and partnerships.